Insulin resistance in Alzheimer's disease

Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of...

Full description

Bibliographic Details
Main Authors: Kelly T. Dineley, Jordan B. Jahrling, Larry Denner
Format: Article
Language:English
Published: Elsevier 2014-12-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996114002642
_version_ 1818646067006144512
author Kelly T. Dineley
Jordan B. Jahrling
Larry Denner
author_facet Kelly T. Dineley
Jordan B. Jahrling
Larry Denner
author_sort Kelly T. Dineley
collection DOAJ
description Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD.Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD.
first_indexed 2024-12-17T00:40:44Z
format Article
id doaj.art-de99f3b2865e480993aa325d75f2553d
institution Directory Open Access Journal
issn 1095-953X
language English
last_indexed 2024-12-17T00:40:44Z
publishDate 2014-12-01
publisher Elsevier
record_format Article
series Neurobiology of Disease
spelling doaj.art-de99f3b2865e480993aa325d75f2553d2022-12-21T22:10:02ZengElsevierNeurobiology of Disease1095-953X2014-12-017292103Insulin resistance in Alzheimer's diseaseKelly T. Dineley0Jordan B. Jahrling1Larry Denner2Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USADepartment of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USADepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA; Corresponding author at: Department of Internal Medicine, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1060, USA.Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD.Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD.http://www.sciencedirect.com/science/article/pii/S0969996114002642Insulin resistanceMetabolismMitochondriaAlzheimer's diseaseAnimal modelsCognitive function
spellingShingle Kelly T. Dineley
Jordan B. Jahrling
Larry Denner
Insulin resistance in Alzheimer's disease
Neurobiology of Disease
Insulin resistance
Metabolism
Mitochondria
Alzheimer's disease
Animal models
Cognitive function
title Insulin resistance in Alzheimer's disease
title_full Insulin resistance in Alzheimer's disease
title_fullStr Insulin resistance in Alzheimer's disease
title_full_unstemmed Insulin resistance in Alzheimer's disease
title_short Insulin resistance in Alzheimer's disease
title_sort insulin resistance in alzheimer s disease
topic Insulin resistance
Metabolism
Mitochondria
Alzheimer's disease
Animal models
Cognitive function
url http://www.sciencedirect.com/science/article/pii/S0969996114002642
work_keys_str_mv AT kellytdineley insulinresistanceinalzheimersdisease
AT jordanbjahrling insulinresistanceinalzheimersdisease
AT larrydenner insulinresistanceinalzheimersdisease